Close

Rodman & Renshaw Downgrades ABIOMED (ABMD) to Market Underperform, Sets $13 Price Target Dec 20, 2011 12:13PM
Rodman & Renshaw Downgrades ABIOMED (ABMD) to Market Underperform Dec 19, 2011 07:50AM
Rodman & Renshaw Upgrades ABIOMED (ABMD) to Market Perform Aug 15, 2011 10:06AM
Rodman & Renshaw Downgrades ABIOMED (ABMD) to Market Underperform, Price Target $6 Dec 8, 2010 09:35AM
Rodman & Renshaw Starts NXTM, THOR, MEND, SPNC at Outperform, EW, SRDX at Underperform Jan 8, 2010 11:34AM